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Abstract
Background: "Protein-trap" is a method that allows epitope-tagging of endogenous proteins. This
method allows for the identification of endogenously expressed proteins that exhibit specific
localization of interest. This method has been recently reported for its application in the study of
Drosophila development by using a relatively large epitope, green-fluorescent-protein (GFP).
Result: Herein, we report a new "protein-trap" vector for mammalian cells. This new method
utilizes a much smaller epitope-tag and also allows for drug-selection prior to the epitope-tagging.
Pre-selection by drug resulted in the highly efficient protein-trapping frequency.
Conclusion: The "protein-trap" method based on this new vector is expected to serve as a
complimentary approach to the previously reported GFP-based method.
Background
Protein-trap is a method that allows for the identification
of proteins of interest based on their unique subcellular
localization without the use of specific antibodies to each
protein. Protein-trap is a complimentary approach to cur-
rently available gene screening methods that are all based
on the detection of global changes in gene expression at a
genome level [1-3].
In another class of gene-expression based approach is
gene-trap. This method uses reporters such as lacZ and
GFP to tag, mutate and identify insertions into endog-
enous genes [4-6]. In addition to the regulation of gene
expression, protein localization also plays a critical role in
many biological processes. Despite such importance, a
method was lacking that allows for the detection of a fam-
ily of proteins based on their unique cellular localization
in a relatively global manner. The modification of original
gene trap approaches was used to identify specifically
secreted or transmembrane proteins [7]. However, more
universal method to screen proteins based on their subcel-
lular localization would be useful. Such a method would
require a large panels of specific antibodies to each pro-
tein. This is theoretically possible but is not a trivial prob-
lem in practice. Protein-trap was invented to overcome
this problem.
The concept of protein-trap was originally proposed by
Smith and Jarvik et al [8,9]. The principle is to tag proteins
by an epitope and localize epitope-tagged proteins by
using specific antibodies against the epitope. This concept
was later adapted using GFP as a tag, thus eliminating the
use of antibodies [10-12]. However, these original ver-
sions (Version 1.x; v1.x) of protein-trap schemes use
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cDNA-GFP fusion library or genomic fragemnts fused to
GFP. Therefore, they do not offer useful information
about the regulation of endogenous protein expression.
Most recently, the second version (Version 2.0; v2.0) of
protein-trap strategy was reported by introducing a GFP
based protein-trap vector into the genome of Drosophila
[13]. This strategy allowed the GFP epitope-tagging of
endogenous proteins in vivo. Thus, the protein-trap v2.0
can be used to identify proteins of interest based on their
subcellular localization in Drosophila without the use of
specific antibodies to each protein.
In this report, we describe a modified version (Version
2.1; v2.1) of a protein-trap scheme that utilizes smaller
epitope-tag (43 amino acids length) and allows for the
trapping of endogenously expressed proteins in mamma-
lian cells. This new epitope-tag (43 amino acids) is con-
siderably smaller than GFP (approximatley 239 amino
acids) used in the protein-trap v2.0. Herein, we report the
protein-trap v2.1 scheme and its unique applications to
the mammalian cells.
Results
Principle of protein-trap v2.1
Our protein-trap v2.1 method is schematically described
in Fig. 1A. The principle of this method is based on
epitope-tagging each protein by a small identifiable
epitope sequence (43 amino acids) at a genome level. The
usefulness of this principle was previously proposed, but
has never been developed for the use for endogenously
expressed proteins at a genome level [9].
The myc-epitope that is commonly used for tagging pro-
teins is inserted as a single copy "mini-exon" into the
genome (Fig. 1A). This mini-exon behaves like a normal
exon as the epitope sequence is flanked by splice-acceptor
and -donor sequences. When the mini-exon is inserted
into an intron of an expressed gene, the protein product is
expressed as a myc-tagged form. Therefore, both intracel-
lular and extracellular localization of the protein can be
identified by a commonly used monoclonal antibody
against the myc-epitope, 9E10 (Fig. 1A).
The protein-trap v2.1 is designed for its specific applica-
tion to mammalian cells. For this specific application, we
have devised a vector called "EpiTag" (Fig. 1B). This vector
uses smaller epitope sequences (43 amino acids) in the
mini-exon than GFP-tag (approximately 239 amino
acids), as the smaller epitope-tag is potentially less detri-
mental to the normal localization of the proteins [14].
The efficient epitope-tagging was accomplished by two
modifications. First, the mini-exon used in EpiTag vector
reads the identical myc-epitope-tag sequences in all three
reading-frame, thus eliminating the use of three inde-
pendent mini-exon constructs. The efficiency was further
improved by incorporating a puromycin-resistant cassette
in the vector. This vector ("EpiTag" vector) can be deliv-
ered into the genome of cells in culture. The cells that
incorporated this EpiTag vector into expressed genes
become puromycin-resistant (Fig. 1B). Therefore, each
puromycin-resistant colony represents a single independ-
ent expressed gene. Approximately 600 puromycin-resist-
ant colonies were typically obtained from the infection of
5 × 105 cells. Upon excision of the puromycin-resistant
gene by Cre-recombinase, each gene becomes epitope-
tagged by the myc-sequence (Fig. 1B).
Retrovirus vector was used to enhance the probability of
integration as a single-copy. In order to provide an esti-
mate on the percentage of successful single-site integra-
tion events, Southern blot analysis was performed (Fig.
1C). This Southern blot analysis indicates that approxi-
mately 80% of the clones represent single-site integration
events.
Identification of epitope-tagged proteins by protein-trap 
v2.1
Using the EpiTag vector, we successfully established a
library of puromycin-resistant clones. Cre-mediated exci-
sion of the puromycin-cassette and the staining of total
5,670 puromycin-resistant colonies with 9E10 antibody
identified 596 epitope-tagged clones. This is approxi-
mately 10% efficiency. The identity of proteins that are
epitope-tagged from a total of 24 myc-antibody positive
puromycin-resistant clones were determined by 3'-RACE
(Table 1). Some of the proteins were trapped multiple
times (e.g., three independent clones each representing
the trapping of the same protein, 40S ribosomal protein
S12).
Intracellular proteins exhibited the known localization
(Fig. 2). Examples of three known nuclear localized pro-
teins are shown in Fig. 2A. The nuclear localization of the
myc epitope-tagged proteins was confirmed by co-stain-
ing with DAPI (Fig. 2A). One cytoskeletal protein was
trapped (beta-actin:ACTB) (Fig. 2B). The co-staining with
FITC-phalloidin confirmed the cytoskeletal localization
of the myc epitope-tagged actin protein (Fig. 2B). Exam-
ples of mitochondrial proteins are shown in Fig. 2C. Colo-
calization of epitope-tagged F1-beta-ATPase (ATP5B) was
confirmed by staining with both anti-myc antibody and
commercially available anti-ATP5B antibody (Fig. 2C).
Another mitochondrial protein, phosphate carrier precur-
sor isoform 1b (PC) also exhibited the known mitochon-
drial localization (Fig. 2C).
In addition to intracellular proteins, one secreted protein,
plasminogen activator inhibitor, was also identified by
the ELISA assay among 5,670 puromycin-resistantBMC Cell Biology 2004, 5 http://www.biomedcentral.com/1471-2121/5/8
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Principle of in vivo epitope-tagging method Figure 1
Principle of in vivo epitope-tagging method. (A) The concept of the method is schematically shown. The mini-exon consisting 
of a synthetic myc-epitope sequence flanked by splice-acceptor and -donor sequences is integrated into an intron of a gene as 
a single copy. This permits the incorporation of an epitope-tag sequence within a protein coding sequences. Secreted proteins 
can be detected by ELISA using 9E10 antibody, a commonly used antibody against the myc-epitope sequence [26]. Intracellular 
protein localization can be detected by immunostaining method using 9E10 antibody. (B) "EpiTag" vector and its mode of 
operation. EpiTag vector consists of a puromycin-resistant gene cassette flanked by a pair of loxP sequences that preceeds the 
mini-exon cassette. The puromycin-resistant cassette consists of a synthetic splice acceptor sequence followed by internal 
ribosomal entry sequence (IRES) fused to the puromycin-resistant sequence that is followed by poly-adenylation sequences. 
When this vector integrates into an intron, the endogenous protein is expressed as a truncated form but the puromycin-resist-
ant marker is also expressed using the second translation start site in IRES. As a consequence, the cells survive in puromycin 
containing media. When the puromycin-resistant cassette is excised by Cre-recombinase, the protein is expressed as a full 
length and as a myc-epitope tagged form. Unique restriction enzyme site, XbaI, in the construct is indicated. The probe used 
for Southern blot analysis is also indicated. (C) Southern blot analysis to determine the number of integration events of EpiTag 
transgene per single cell (clone). Results from ten independent clones are shown. The XbaI-digested DNA was analyzed. Sin-
gle-band indicates a single-site integration event. Multiple-bands indicate a single-copy but a multiple-site integration event. The 
clone numbers are indicated at the top and the ones that show a multiple-site integration event are indicated with (*). This 
result indicates approximately 80% of the clones represent single-site integration events of the transgene. S7B2: beta-actin; 
L1E4:beta ATP synthase; S6E11:CD44 antigen; S5F3:dual specificity protein phosphatase 5; L1A9:enolase alpha; S5A9:integrin 
alpha6; L2C11:phosphate carrier precursor isoform 1b; F1A5:similar to prokaryotic-type class I peptide chain release factors; 
S6G11:ribosomal protein L3; F1A3:40S ribosomal protein S12; S5E5:40S ribosomal protein S19.BMC Cell Biology 2004, 5 http://www.biomedcentral.com/1471-2121/5/8
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colonies (Fig. 3). These results confirm that the protein-
trap v2.1 scheme using EpiTag vector is effective in
epitope-tagging both intracellular and extracellular
proteins.
Sequence identification by RACE reactions shows the
insertion of the myc mini-exon epitope in the expected
exon/exon boundaries in proteins (Figure 4). For hetero-
geneous ribonucleoprotein, two independent insertion
events exibit the identical localization pattern (Fig. 2A).
This suggested that epitope-location within the full-length
heterogeneous ribonucleoprotein A1 does not affect its
normal localization.
Epitope-tagged proteins are synthesized as full-length 
proteins
The translation products of epitope-tagged ATP5B and
ACTB was studied by Western blot analysis (Fig. 5). These
two proteins were selected for the Western blot analysis
since specific antibodies for these proteins that are suited
for Western blot analysis are readily available. The West-
ern blot analysis of ATP5B and ACTB confirmed that the
epitope-tagged proteins are synthesized as expected full-
length sizes (Fig. 5). Furthermore, the translation of
epitope-tagged proteins is specifically dependent on Cre-
mediated excision of puromycin-cassette (Fig. 5). The syn-
thesis of full-length proteins is also reflected on the tran-
scription of full-length mRNA based on the RACE
reaction. Only exception to this fidelity of the system is
the integrin α6 (Table 1). In the case of integrin α6, the
epitope-encoding mini-exon was inserted into the intron
1. However, mini-exon is spliced into the cryptic splice-
donor site present at the downstream part of the intron 1.
This resulted in the truncation of normal integrin α6
protein.
Application of protein-trap v2.1 screening to identify 
protein translocations upon extracellular signals
Commonly used gene expression based screening identi-
fies genes that are turned on and off in response to a vari-
ety of signals such as cell proliferation and differentiation,
and exposure to chemical and physiological signal [1-3].
However, these differential gene expression based screen-
ing methods fail to identify proteins that are constitutively
expressed but alter their localizations in response to such
signals.
Protein translocation is known to play a critical role in a
variety of biological processes. Identification of proteins
that translocate in response to specific signals has been
conventionally achieved by examining the translocation
of each protein in response to specific signals. This
approach requires targeted examination of specific pro-
teins with specific prior hypotheses and predictions. It
also requires the availability of useful antibodies to local-
ize such proteins. To bypass these limitations, it would be
extremely useful if a family of proteins that may play
important biological functions by translocation can be
identified without prior hypotheses and predictions. The
success in this type of "reverse-genetic" approach provides
more opportunities to study a variety of biological proc-
esses from different angles.
Table 1: Examples of trapped proteins.
Protein name Localization AC# INCIDENCE MYC insertion
40S ribosomal protein S12 cytoplasm X53505 3 E2/E3, E3/E4
40S ribosomal protein S19 cytoplasm AF092907 1 E1/E2
Beta actin cytoskeleton M10277 1 E1/E2
Beta ATP synthase mitochondrion M27132 1 E1/E2
CD44 antigen membrane AJ251595 2 E1/E2
Dual specificity protein phosphatase 5 nucleus U15932 1 E1/E2
Enolase alpha cytoplasm X16287 1 E2/E3
Eukaryotic translation initiation factor 1A cytoplasm L18960 1 E1/E2
Heterogeneous nuclear ribonucleoprotein A1 nucleus X12671 3 E1/E2, E2/E3
Integrin α6 membrane X53586 1 * * *
Metallothionein 2A cytoplasm J00271 2 E2/E3
Phosphate carrier precursor isoform 1b mitochondrion X60036 2 E3/E4
Plasminogen activator inhibitor, type 1 secreted M16006 2 E2/E3
Regulator of chromosome condensation 1 nucleus D00591 1 E5/E6
Ribosomal protein L3 cytoplasm BC008492 1 E2/E3
Similar to prokaryotic-type class I peptide chain release 
factors
mitochondrion BC011873 1 E6/E7
* * * Insertion was in intron 1 and a cryptic translation of the intron sequence occurred possibly due to a splicing to a cryptic splice acceptor 
sequence in the intron.BMC Cell Biology 2004, 5 http://www.biomedcentral.com/1471-2121/5/8
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Examples of intracellular localized epitope-tagged proteins Figure 2
Examples of intracellular localized epitope-tagged proteins. (A) Nuclear localized proteins (Heterogeneous ribonucleoprotein 
A1: HRNPA1, chromosome condensation1: CHC1). Their nuclear localization was confirmed by co-staining with DAPI. In the 
case of HRNPA1, two clones that incorporated the epitope-tag in the two distinct part of the proteins were isolated. How-
ever, both of these epitope-tagged HNRPA1 (N1B1 and N1A10) exhibited the identical localization pattern. (B) Cytoskeletal 
protein. Beta-actin was epitoped tagged. The co-staining of the cells with anti-myc antibody and FITC-phalloidin confirmed the 
colocalization. (C) Mitochondrial proteins (F1-beta-ATPase: ATP5B, phosphate carrier precursor isoform 1b: PC). The 
epitope-tagged ATB5B and endogenous ATB5B proteins exhibited the identical localization as shown by co-staining the cells 
with anti-myc and anti-ATP5B antibodies. Since no useful antibodies against PC are available, the cells were co-stained with 
anti-myc and Mitotracker Green FM (Molecular Probes). Both anti-myc and Mitotracker FM showed identical staining, confirm-
ing the mitochondrial localization of epitope-tagged PC protein. All of the colocalization studies were preformed with confocal 
microscopy. Only the cells that underwent the successful Cre-mediated excision express the myc-tagged proteins and were 
stained with 9E10 antibody. The efficiency of Cre-mediated excision varied greatly depending on the target gene (<0.5% – 2%).BMC Cell Biology 2004, 5 http://www.biomedcentral.com/1471-2121/5/8
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To test the applicability of our protein-trap v2.1 scheme in
accomplishing this goal, we attempted to identify proteins
that are constitutively expressed but alter their subcellular
localizations in response to hypoxia. Hypoxia is one of
the most critical biological signals for nearly all cells [15-
17]. A large number of genes have been previously identi-
fied for their differential expression in cells in response to
hypoxia [18-20]. However, very little is known about
putative pathways that may not be directly linked to gene
expression but yet play critical roles in cells' response to
hypoxia. Therefore, we tested whether there are proteins
that change their cellular localizations in response to
hypoxia by using the protein-trap v2.1 (Fig. 6A).
Each puromycin-resistant colony following the insertion
of the EpiTag vector was picked individually and arrayed
onto 96-well culture plates (Fig. 6A). Master plates were
stored and duplicate tester plates were subjected to Cre-
recombinase mediated excision of the puromycin-resist-
ant gene (Fig. 6A). One of the duplicate plates was cul-
tured in normoxic and the other in hypoxic conditions
(Fig. 6A). The myc-epitope tagged proteins were detected
with the 9E10 antibody and immunofluorescence stain-
ing patterns were compared (Fig. 6A).
Using this screening scheme, we have identified a protein
that changes subcellular localization upon hypoxia treat-
ment (Fig. 6B). It is eukaryotic translation initiation factor
1A (EIF1A). In normoxia, its localization is patchy but
ubiquitously distributed throughout the cytoplasm (Fig.
6B). In hypoxia, the EIF1A localization was specifically
detected in a fibrous pattern similar to β-actin localization
(Fig. 2).
To confirm that this staining pattern change is due to the
protein translocation of the same protein, Western blot
analysis was performed (Fig. 6C). Unavailability of an
useful antibody for EIF1A forced us to resort to this indi-
rect method. The Western blot analysis clearly shows that
the protein of identical molecular weight is detected in the
lysates prepared from the cells cultured in both normoxia
and hypoxia conditions (Fig. 6C). Although further stud-
ies are necessary, this result provides evidence that EIF1A
translocates upon hypoxia.
The identification of EIF1A as a protein that translocates
in response to hypoxic environment was achieved without
prior prediction. Therefore, this result implicates that our
protein-trap v2.1 scheme can be adapted to discover
Trapping of secreted proteins Figure 3
Trapping of secreted proteins. ELISA was used to detect 
secreted epitope-tagged protein in the media. Position 
number 4 in this case identifies a significantly high signal. Fol-
lowing the screening of total 5,670 clones, two clones gave 
significantly high ELISA signals. One was identified as plas-
minogen activator I (PAII). However, the other clone failed 
to yield consistent sequencing result following the 3'-RACE 
reaction. Thus the protein identity of this second clone 
remains unknown.
Epitope insertion site in each gene Figure 4
Epitope insertion site in each gene. RACE analysis confirmed 
that the epitope is inserted precisely at the known exon/
exon boundaries in analyzed proteins. The mini-exon is indi-
cated as a grey box in each gene. The position of the myc-
epitope relative to the full-length protein for each gene is 
indicated by an amino acid position (indicated as a number). 
HRNPA1: heterogeneous nuclear ribonucleoprotein A1; 
CHC1: regulator of chromosome condensation 1; SLC25A3: 
phosphate carrier precursor isoform 1b; ATP5B: beta-ATP 
synthase; SERPINE1: type 1 plasminogen activator inhibitor; 
ACTB: beta-actin.BMC Cell Biology 2004, 5 http://www.biomedcentral.com/1471-2121/5/8
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protein translocation events in response to a specific bio-
logical signal without any prior hypotheses or predictions.
Discussion
New feature of protein-trap v2.1
In this report, we described a modified protein-trap
scheme for endogenous proteins. There are a few unique
features with our protein-trap v2.1. First, our epitope-tag
encoded by a mini-exon is considerably smaller (43
amino acids) as compared to GFP (239 amino acids).
Although GFP is frequently used to tag proteins, a smaller
tag such as myc may potentially have less effect on the
normal protein localization. Furthermore, the myc-tag is
commonly used as a tag for a variety of proteins.
The second unique feature is that our mini-exon encodes
43 amino acid peptides that contain the myc-epitope in
all three reading frames without any interrupting stop
Synthesis of full-length epitope-tagged proteins Figure 5
Synthesis of full-length epitope-tagged proteins. Epitope-
tagged ATP5B and ACTB proteins were analyzed by West-
ern blot to confirm the translation of full-length proteins. 
The Western blots were first probed with anti-myc antibody 
and secondly with anti-ATP5B or anti-ACTB following the 
stripping of the anti-myc antibody. Cell lysates before (-Cre) 
and after (+Cre) the Cre-mediated excision of the SA-IRES-
puromycin cassette were analyzed. Specific myc-epitope sig-
nal (••) was detected from the (+Cre) cell lysates. No myc-
epitope signal was detected from the (-Cre) cell lysates. Anti-
ATP5B and anti-ACTB detected both endogenous ATP5B 
and ACTB proteins (••••), respectively, in addition to the 
epitope-tagged corresponding proteins (••). Slight size differ-
ence (approximately 3–4 kDa) between the epitope-tagged 
protein (••) and the endogenous counterpart of each protein 
(••••) reflects the addition of the mini-exon encoded epitope-
tag. The "+cre" cell lysates were prepared from the cells that 
were transiently infected with the cre virus. Thus, they are 
mixtures of cells that express the tagged proteins and the 
cells that do not. As the cre-mediated excision efficiency is in 
the range of 0.5%-2%, the myc-tagged protein bands are 
always stained less intense. Molecular weight (in kDa) stand-
ards are also indicated.
The screening for a family of proteins that translocates in  hypoxia Figure 6
The screening for a family of proteins that translocates in 
hypoxia. (A) Screening scheme. A single copy of EpiTag vec-
tor is inserted into the genome by replication-defective ret-
rovirus. Following integration of the vector, cells were 
selected by puromycin and each puromycin-resistant colony 
was picked and replated to 96-well cell culture plates individ-
ually. The master plates were stored frozen and the duplicate 
tester plates were generated. Both tester plates were sub-
jected to the infection by another replication-defected retro-
virus expressing Cre-recombinase. One of the tester plates 
was cultured in normoxia and the other tester plate was cul-
tured in hypoxia. Following incubation in each environment 
for 18 hrs, cells were fixed and stained with 9E10 antibody 
and staining patterns were analyzed using Axiovert 200 M 
microscope (Carl Zeiss) equipped with a motorized auto-
mated stage and fluorescence filters using Open Lab Image 
analysis software (Improvision). (B) Translocation of 
epitope-tagged EIF1 in response to hypoxia. In normoxia, 
epitope-tagged EIF1 is localized ubiquitously in cytoplasm in a 
patchy manner. In hypoxia, its localization shifts to fibrous 
pattern resembling actin cytoskeleton. (C) Western blot 
analysis of the cell lysates. The blot was probed with anti-myc 
antibody. The protein with the same molecular weight was 
detected in the lysates prepared from the cells cultured in 
normoxia and hypoxia conditions. The size of the protein 
band is in accordance with the known molecular weight of 
EIF1A protein.BMC Cell Biology 2004, 5 http://www.biomedcentral.com/1471-2121/5/8
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codons [9]. This reading-frame independent epitope-tag-
ging eliminates the use of three protein-trap vectors.
The third feature is the incorporation of the puromycin-
selection cassette into the vector. The incorporation of a
puromycin-resistant cassette enables the cells to survive in
puromycin-containing media when the cells incorporated
the protein-trap vector in the expressed gene locus. This
puromycin-cassette can be removed by a simple Cre
recombinase transduction, which subsequently results in
the myc-epitope tagging of the trapped protein (Fig. 1B).
By this pre-drug selection, we were able to achieve rela-
tively efficient protein-trapping frequency (approximately
10% of the puromycin-resistant clones expressed detecta-
ble levels of tagged-proteins).
The last unique feature is the ability to trap both intracel-
lular and extracellular proteins with our scheme (Fig. 2
&3). The myc epitope-tagged secreted proteins were
detected through the use of two different antibodies for
mini-exon encoded epitopes in the sandwich ELISA for-
mat (Fig. 3).
Potential applications of protein-trap v2.1 in mammalian 
cells
Our protein-trap v2.1 method can be adapted to discover
proteins of interest based on a number of criteria in mam-
malian cell culture system. The most straightforward
approach is to identify proteins simply by their unique
cellular localizations. For example, one could use this
method to identify proteins that exhibit interesting distri-
butions in nucleus during cell division or at the cell-cell
junction.
Our scheme can be also used to identify proteins that
translocate in response to biological, physiological or
chemical signals. As an example of this type of applica-
tion, we showed the scheme to identify proteins that
translocate in response to hypoxic condition (Fig. 5). In
this report, we tested our system only with one signal,
hypoxia. However, our system can be adapted to identify
proteins that translocate in response to a large number of
different signals.
Another application is to screen for agonists and antago-
nists causing the specific cellular localization of the pro-
tein by using an identified clone of cells that express a
unique epitope-tagged protein. This would be useful
especially when the regulated specific cellular localization
of the protein is critical for its function.
In this paper, we have established proof-of-principle of a
new protein-trap method with human lung carcinoma
cell line, NCI-H1299. However, this method is expected
to work in other cells. One of the most potentially useful
cells is embryonic stem (ES) cells. ES cells can be main-
tained as undifferentiated and subsequently induced to
differentiate to a variety of cell types in vitro. Therefore, it
is possible to identify translocatable proteins upon ES cell
differentiation.
Potential further improvements of protein-trap v2.1
Although our protein-trap v2.1 is useful for a number of
reasons discussed above, there is room for further
improvement in the future. Our currently described
EpiTag vector is based on a retrovirus-mediated integra-
tion. However, the LTRs that remain in the genome could
affect the expression of other genes near the integration
site. Furthermore, the retroviral vector could integrate into
"hot spots" in the genome. These preferential integration
events could result in biased representation of the trapped
proteins. Therefore, it would be useful to have an option
to be able to use non-viral integration method such as
transposon system in mammalian cells in the future [21].
The frequency of the protein-trapping events in our sys-
tem is currently 1/10. This suggests that 9 out of 10 puro-
mycin-resistant clones remain unstained for the epitope-
tag. Although there could be some leakiness in the puro-
mycin-selection, it is also possible that 9E10 antibody
staining method to detect the epitope-tagged proteins
may not be sensitive enough to detect all of the epitope-
tagged proteins. When the abundance of the epitope-
tagged proteins is low in the cell, the cells become puro-
mycin-resistant but the amount of the tagged protein
could be insufficient to be detected by 9E10 antibody.
Therefore, it would be useful to invent a way to enhance
the sensitivity of the immuno-detection method in the
future.
The major advantage of the use of GFP as a protein-trap-
ping tag is its autofluorescent nature of the molecule. This
eliminates the use of antibodies to detect the trapped pro-
teins, thus allowing visualization in living organisms. Our
protein-trap v2.1 uses smaller epitope-tag but requires the
use of antibody to detect the epitope-tagged protein.
Therefore, it would be further useful to invent a mini-exon
cassette that encodes a small amino acid sequences of
which expression can be detected without a specific
antibody.
Conclusions
Herein, we present a new protein-trap system that is spe-
cifically applicable to mammalian cells. This system
allows for the discovery of proteins based on their unique
localization. The protein-trap system is expected to
compliment other genomic and proteomic approaches in
search of proteins that play critical roles in a variety of bio-
logical and/or pathological processes.BMC Cell Biology 2004, 5 http://www.biomedcentral.com/1471-2121/5/8
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Methods
Constructs and virus
The EpiTag vector was generated by fusing the splice
acceptor (SA) originating from the intron/exon2 bound-
ary of adenovirus (kindly provided by Phil Soriano) to the
IRES::Puromycinr::pA cassette of the pIRESpuro vector
(Clonetech). This SA::IRES::puromycinr::pA cassette was
flanked by a pair of loxP sequences. The mini-exon cas-
sette was kindly provided by Desmond Smith and is pre-
viously described [9]. The final construct containing
puromycin and mini-exon cassettes was inserted into the
XhoI site of the replication-defective retrovirus vector,
pGen-  (kindly provided by Phil Soriano), in reverse
orientation.
The retrovirus vector expressing Cre-recombinase was
generated by replacing the lacZ sequence of the LZR-
SpBMN-Z (kindly provided by Gary Nolan) with the Cre-
NLS (kindly provided by Stephen O'Gorman) [22,23].
Replication-defective retrovirus was packaged using the
Phoenix cell line (kindly provided by Gary Nolan) as
described before [24].
"EpiTag virus stock" was prepared by collecting the media
from the Phoenix cells transiently transfected with the
constructs as described above. "Cre virus stock" was pre-
pared by collecting the media from the Phoenix cells that
were stably transfected with the retrovirus vector contain-
ing the Cre-NLS described above.
Cell culture
NCI-H1299 cells (human lung carcinoma cell line) were
cultured in 10%FCS, RPMI1640, penicillin, streptomycin
and infected with EpiTag vector virus. NCI-H1299 cells (5
× 105 cells in a 10 cm plate) were infected with 2 ml of
"EpiTag virus stock". Two days post infection, the media
was replaced with the addition of 1.75 µg/ml puromycin.
The cells grown in this selection media for 7–10 days and
the puromycin-resistant colonies were picked and trans-
ferred to 96-well cell culture plates. The master plates were
stored at -80°C and duplicate tester plates were subjected
to infection by Cre virus to remove the SA::IRES::puromy-
cinr::pA cassette. Cells in each well of 96-well plates
received 50 µl of "Cre virus stock". Following Cre virus
infection, cells were cultured in normoxic or hypoxic con-
ditions, and stained with 9E10 antibody to localize the
myc-epitope tagged proteins. Concurrently, the culture
media was assayed for the potential presence of secreted
myc-epitope tagged protein by ELISA.
Hypoxia was achieved by infusing a gas mixture (95% N2/
5% CO2) into an air chamber (Billups-Rothenberg) as
described before [25]. The plates in the hypoxia chamber
and the ones in normoxia (95% air/5% CO2) were always
cultured and assayed at the same time.
Immunofluorescence staining and ELISA
Cells were fixed and permeablized by 1% TritonX-100,
3.6% paraformaldehyde in PBS at 4°C for 10 min. Non-
specific binding sites were blocked by 2% BSA, 0.1%Tri-
ton X-100. PBS and the myc-epitope tagged proteins were
detected by using 9E10 antibody (conditioned media pre-
pared from the cultured hybridoma cells purchased from
Developmental Studies Hybridoma Bank) and Cy3-con-
jugated donkey anti-mouse IgG (Jackson
ImmunoResearch).
For the detection of secreted myc-epitope tagged proteins,
the conditioned media from each well was incubated in a
96-well ELISA plate (Nunc) coated with 5 µg/ml affinity
purified rabbit anti-Ep2 epitope IgG. Ep2 is an epitope
(EWSRSSSPRRTST) just outside of the myc-epitope gener-
ated from the mini-exon coding sequence [9]. Rabbit pol-
yclonal anti-Ep2 antibody was prepared by immunizing
rabbits with Ep2 peptide conjugated with carrier proteins.
The bound myc-epitope tagged proteins were subse-
quently detected by 9E10 antibody and HRP-conjugated
goat anti-mouse IgG (Jackson ImmunoResearch).
Western Blot Analysis
Cells were lysed in the SDS-PAGE sample buffer (2% SDS,
10% glycerol, 20 mM DTT, 65 mM Tris-Hcl, pH6.8,
0.05% bromophenol blue). The cell lysates were loaded
onto SDS-PAGE and the proteins were transferred to
Hybond-C Extra membrane (Amersham). The mem-
brane-transferred proteins were probed with rabbit anti-
myc polyclonal antibodies (Cell Signaling Technology) or
corresponding antibodies against the specific endogenous
proteins. The signal was detected by using ECL system
(Amersham).
Southern blot analysis
Each genomic DNA was digested with XbaI. The probe
was labeled with 32P-dCTP using Prime-It II kit (Strata-
gene). The blot was hybridized and washed (final with
0.1XSSC, 0.1%SDS at 67°C) at the highest stringency.
Gene identification
The myc-epitope tagged gene was identified by 3'-RACE
using outer and inner primers derived from the 3'-end of
the mini-exon (outer primer TS862: 5'-GAAGCTCATCTC-
CGAGGAGG-3', inner primer TS863: 5'-AGCTCATCTC-
CGAGGAGGAC-3') and RLM-Race kit (Ambion).
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